Predicting Δ-9-Tetrahydrocannabinol-Induced Psychoactive and Cognitive Effects: A PBPK-PD Approach to Quantifying Feeling High and Reduced Alertness
- PMID: 40694686
- PMCID: PMC12333010
- DOI: 10.1021/acschemneuro.5c00417
Predicting Δ-9-Tetrahydrocannabinol-Induced Psychoactive and Cognitive Effects: A PBPK-PD Approach to Quantifying Feeling High and Reduced Alertness
Abstract
The increasing use of cannabis for medicinal and recreational purposes highlights the need to understand its psychoactive effects. Δ-9-tetrahydrocannabinol (THC), the primary psychoactive cannabinoid, is responsible for feeling high and reduced alertness after cannabis use. This study aimed to develop and verify physiologically based pharmacokinetic-pharmacodynamic (PBPK-PD) models to quantify the effects of THC and its active metabolite, 11-hydroxy-THC, on feeling high and reduction in alertness in healthy adults. The models were developed using Simcyp, based on our previously verified THC PBPK model. A direct response model with a maximum effect (Emax) function driven by the brain concentrations and an effect compartment was used to describe visual analogue scale (VAS) scores for feeling high after intravenous, oral, and inhaled THC administration. An indirect response model with an Emax function driven by the brain concentrations was used to describe the reduction in VAS alertness scores after inhaled THC. Our models accurately captured the dose-response relationships for THC doses ranging from 2 to 86 mg for feeling high, and 2 to 69.4 mg for alertness reduction. The verified PBPK-PD model provides a robust tool for predicting the psychoactive and cognitive effects of THC, enabling improved assessment of cannabis-induced responses across diverse populations.
Keywords: PBPK−PD; alertness; feeling high; pharmacodynamics; psychoactive; Δ-9-tetrahydrocannabinol.
Figures





Similar articles
-
The Pharmacokinetics and Pharmacodynamics of a Hemp-Derived "Full-Spectrum" Oral Cannabinoid Product with a 1:1 Ratio of Cannabidiol to Cannabidiolic Acid and Delta-9-Tetrahydrocannabinol to Delta-9-Tetrahydrocannabinolic Acid: A Double-Blind, Placebo-Controlled, Within-Subjects Human Laboratory Study.Cannabis Cannabinoid Res. 2025 Apr;10(2):e299-e313. doi: 10.1089/can.2024.0187. Epub 2025 Mar 5. Cannabis Cannabinoid Res. 2025. PMID: 40040421 Clinical Trial.
-
A within-subject cross-over trial comparing the acute effects of oral delta-8-tetrahydrocannabinol and delta-9-tetrahydrocannabinol in healthy adults.Drug Alcohol Depend. 2025 Jul 1;272:112676. doi: 10.1016/j.drugalcdep.2025.112676. Epub 2025 Apr 12. Drug Alcohol Depend. 2025. PMID: 40288059 Clinical Trial.
-
The Individual and Interactive Effects of Alpha-Pinene and Delta-9-Tetrahydrocannabinol in Healthy Adults.Med Cannabis Cannabinoids. 2025 Jun 25;8(1):144-157. doi: 10.1159/000547014. eCollection 2025 Jan-Dec. Med Cannabis Cannabinoids. 2025. PMID: 40734690 Free PMC article.
-
The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS.Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD005175. doi: 10.1002/14651858.CD005175.pub3. Cochrane Database Syst Rev. 2013. PMID: 23633327 Free PMC article.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
References
-
- Substance Abuse and Mental Health Services Administration . Results from the 2022 National Survey on Drug Use and Health (NSDUH): Key Substance Use and Mental Health Indicators in the United States, 2023. https://www.samhsa.gov/data/sites/default/files/reports/rpt42731/2022-ns....
-
- Rep. Conaway, K. M. H.R.2Agriculture Improvement Act of 2018, 2018. https://www.congress.gov/bill/115th-congress/house-bill/2/text/enr (accessed March 16, 2025).
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources